Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Myeloid cells comprise a major component of the tumor microenvironment (TME) that promotes tumor growth and immune evasion. By employing a small-molecule inhibitor of glutamine metabolism, not only were we able to inhibit tumor growth, but we markedly inhibited the generation and recruitment of myeloid-derived suppressor cells (MDSCs). Targeting tumor glutamine metabolism led to a decrease in CSF3 and hence recruitment of MDSCs as well as immunogenic cell death, leading to an increase in inflammatory tumor-associated macrophages (TAMs). Alternatively, inhibiting glutamine metabolism of the MDSCs themselves led to activation-induced cell death and conversion of MDSCs to inflammatory macrophages. Surprisingly, blocking glutamine metabolism also inhibited IDO expression of both the tumor and myeloid-derived cells, leading to a marked decrease in kynurenine levels. This in turn inhibited the development of metastasis and further enhanced antitumor immunity. Indeed, targeting glutamine metabolism rendered checkpoint blockade-resistant tumors susceptible to immunotherapy. Overall, our studies define an intimate interplay between the unique metabolism of tumors and the metabolism of suppressive immune cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a prodrug of 6‐diazo‐5‐oxo‐l‐norleucine (DON) that blocks glutamine metabolism in myeloid precursor cells can differentiate monocytes into anti‐tumor TAMs, leading to tumor regression in mouse models [56].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx247 · Cited by 9,849
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · cited 1×
“Yet, in spite of these successes it is clear that not all cancers respond to checkpoint blockade alone and even amongst responsive cancers, not all patients respond (52, 60-62).”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Yet, in spite of these successes it is clear that not all cancers respond to checkpoint blockade alone and even amongst responsive cancers, not all patients respond (52, 60-62).”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 1×
“Macrophages, which constitute a major component of tumors, are involved in cancer initiation, progression, angiogenesis, metastasis, and creating an immune suppressive environment (4-7).”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 1×
“Such an environment favors the residency of suppressive myeloid cells such as MDSCs, TANs, and TAMs, all of which contribute to promoting tumor growth, angiogenesis, metastasis, and immune escape (51).”
BackgroundThe emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 1×
“Alternatively, suppressive immune cells, that are metabolically distinct from effector cells, thrive in the TME (1-3).”
BackgroundPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · cited 1×
“Macrophages, which constitute a major component of tumors, are involved in cancer initiation, progression, angiogenesis, metastasis, and creating an immune suppressive environment (4-7).”
Background
Cited by
Items 101–200 of 471
Li, Q., Zhong, X., Yao, W., Yu, J., Wang, C., Li, Z., Lai, S., Qu, F., Fu, X., Huang, X., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101753 · Cited by 65
“When mice were treated with JHU083 combined with anti-PD-1 or anti-CTLA4, further tumor regression was achieved than JHU083 monotherapy group (41).”
BackgroundMitochondria orchestrate macrophage effector functions in atherosclerosis
Dumont, A., Lee, M., Barouillet, T., Murphy, A. J., & Yvan‐Charvet, L. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100922 · Cited by 60
Metabolism in the progression and metastasis of brain tumors
Tyagi, A., Wu, S.-Y., & Watabe, K. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215713 · Cited by 63
“Emerging evidence have shown that inhibition of metabolic reprogramming induced by glutamine in tumor cells caused drastic reduction in MDSCs recruitment to the tumor bed, thereby influencing tumor cell growth and metastasis [100].”
BackgroundAllavena, P., Anfray, C., Ummarino, A., & Torres, F. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1679 · Cited by 58
“A small prodrug molecule (6-diazo-5-oxo-L-norleucine) was used to block glutamine metabolism in a mouse breast cancer model, showing inhibited tumor growth and metastases not only by acting on tumor cells, but also by enhancing macrophage activation and reducing immunosuppression (71).”
MethodRethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer
Ni, R., Li, Z., Li, L., Peng, D., Ming, Y., Li, L., & Liu, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1143798 · Cited by 66
Metabolites as agents and targets for cancer immunotherapy
Trefny, M. P., Kroemer, G., Zitvogel, L., & Kobold, S. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01227-z · Cited by 66
“In a key mechanism, kynure-nine activates aryl hydrocarbon receptor (AHR), which induces differentiation of regulatory T cells (T reg cells) and tumour infiltration by myeloid-derived suppressor cells (MDSCs) 20,21 .”
InfluentialKaushik, A., Tarangelo, A., Boroughs, L. K., Ragavan, M., Zhang, Y., Wu, C., Li, X., Ahumada, K., Chiang, J., Tcheuyap, V. T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abp8293 · Cited by 62
Self-citationOvercoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells
Qin, G., Liu, S., Liu, J., Hu, H., Li, Y., Zhao, Q., Li, C., Zhang, B., & Zhang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01388-6 · Cited by 56
Glutamine metabolic reprogramming in hepatocellular carcinoma
Ye, Y., Yu, B., Wang, H., & Yi, F. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1242059 · Cited by 61
“JHU-083 is a pro-drug proven to inhibit tumor growth and reshape the tumor immune microenvironment, promoting CD8+T activation and proliferation and decreasing immunosuppressive myeloid cells (Oh et al., 2020).”
BackgroundGoverna, V., de Oliveira, K. G., Bång-Rudenstam, A., Offer, S., Cerezo-Magaña, M., Li, J., Beyer, S., Johansson, M. C., Månsson, A., Edvardsson, C., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk1168 · Cited by 57
Host cell glutamine metabolism as a potential antiviral target
Hirabara, S. M., Gorjão, R., Levada‐Pires, A. C., Masi, L. N., Hatanaka, E., Cury‐Boaventura, M. F., da Silva, E. B., dos Santos-Oliveira, L. C., Diniz, V. L. S., Serdan, T. D. A., et al. (2021) · Clinical Science · doi:10.1042/cs20201042 · Cited by 59
Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer
Viel, S., Vivier, É., Walzer, T., & Marçais, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01098-w · Cited by 66
“Moreover, glutamine inhibition can also be considered in combination with other drugs due to its synergy with immune-checkpoint inhibitors to promote antitumour immunity 183,185 .”
Luo, J., Guo, M., Huang, M., Liu, Y., Qian, Y., Liu, Q., & Cao, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02158-2 · Cited by 64
“34,35 The restricted nutrition is primarily due to a poor supply caused by the presence of myeloid-derived suppressor cells (MDSC) and tumor cells, 36,37 consequently diminishing the tumor-fi ghting capacity and persistence of CAR-NK cells.”
Comorbidity-associated glutamine deficiency is a predisposition to severe COVID-19
Matsuyama, T., Yoshinaga, S. K., Shibue, K., & Mak, T. W. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00892-y · Cited by 59
“While hyperinflammation due to proinflammatory cytokine overproduction has been frequently documented, it is recently recognized that the immune response is markedly suppressed in some cases by the expansion and activity of MDSCs (myeloid-derived suppressor cells) and FoxP3+ Tregs (regulatory T cells).”
BackgroundInfluentialZhang, K., Li, Y., Peng, L., Gao, H., Liu, L., & Chen, H. H. (2023) · Biology Direct · doi:10.1186/s13062-023-00356-y · Cited by 55
“Studies have demonstrated that M2 macrophage-derived exosomes facilitate T-cell exhaustion in liver cancer [10], enhance invasion in colon cancer, and regulate BRG1 expression in response to TME [11].”
BackgroundInfluentialXiao, L., Wang, Q., & Peng, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1157291 · Cited by 59
Udumula, M. P., Sakr, S., Dar, S. A., Alvero, A. B., Ali‐Fehmi, R., Abdulfatah, E., Li, J., Jiang, J., Tang, A., Buekers, T., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101272 · Cited by 57
“com metabolism in many types of cancers, enhanced tumor-specific immunity by changing the function of myeloid cells [35,40,44].”
BackgroundMethodFueling the Revolution: Targeting Metabolism to Enhance Immunotherapy
Leone, R. D., & Powell, J. D. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0791 · Cited by 57
“Interestingly, blocking glutamine metabolism also has the added benefit of leading to decreased kynurenine production by inhibiting the expression of IDO (44).”
BackgroundSelf-citationTargeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment
Yamamoto, K., Iwadate, D., Kato, H., Nakai, Y., Tateishi, K., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184351 · Cited by 53
“Notably, this immune modula ory effect of glutamine metab lism bl ckade was also demonstrated in studies using a new y developed pr drug of DON, JHU083, against colon cancer, lymphom , and melanoma, in which JHU083 treatment showed synergistic effects with immune checkpoi t blo kade therapy [51,52].”
BackgroundResultHan, Z., Zhang, C., An, J., Wang, Y., Qiao, J., Zeng, X., & Zhang, X. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202302728 · Cited by 53
Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy
Zhang, H., Fan, J., Kong, D., Sun, Y., Zhang, Q., Xiang, R., Lu, S., Yang, W., Feng, L., & Zhang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02460-1 · Cited by 58
“Additionally, studies have shown that inhibition of glutamine metabolism suppresses tumor proliferation while impairing MDSC expansion and recruitment, which correlates with reduced expression of tumor-derived colony-stimulating factor 3 [220].”
Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer
Kandra, P., Nandigama, R., Eul, B. G., Huber, M., Kobold, S., Seeger, W., Grimminger, F., & Savai, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903562 · Cited by 56
Genetically Programmable Vesicles for Enhancing CAR‐T Therapy against Solid Tumors
Li, X., Zhu, T., Wang, R., Chen, J., Tang, L., Huo, W., Huang, X., & Cao, Q. (2023) · Advanced Materials · doi:10.1002/adma.202211138 · Cited by 55
Wu, Z., Liu, P., Huang, B., Deng, S., Song, Z., Huang, X., Yang, J., & Cheng, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-33277-x · Cited by 54
Metabolic engineering for optimized CAR-T cell therapy
McPhedran, S. J., Carleton, G. A., & Lum, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00976-2 · Cited by 56
“Tumour cells (primarily) 106 , CAFs 107 Inhibits T cell killing capacity and cytokine production (IFN-γ and IL-2) 49 , promotes the formation of MDSCs, TAMs and T reg cells 50 Adenosine Tumour cells 108 , MDSCs 109 , CAFs, mesenchymal stem cells and stromal cells, endothelial cells, TAMs, T reg cells 110 Negatively re…”
InfluentialMetabolic Cancer-Macrophage Crosstalk in the Tumor Microenvironment
de Goede, K. E., Driessen, A. J. M., & den Bossche, J. V. (2020) · Biology · doi:10.3390/biology9110380 · Cited by 56
Neutrophil metabolism in the cancer context
Bodac, A., & Meylan, E. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101583 · Cited by 52
“In patients with head and neck cancer and non-small cell lung cancer (NSCLC), it has been shown that PMN-MDSCs overexpress the lectintype oxidized low-density lipoprotein (LDL) receptor-1 (LOX-1) that binds oxidized lipoproteins.”
BackgroundInfluentialThe Role of Tumor Metabolic Reprogramming in Tumor Immunity
Zhang, X., Song, W., Gao, Y., Zhang, Y., Zhao, Y., Hao, S., & Ni, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417422 · Cited by 54
Polyamines: the pivotal amines in influencing the tumor microenvironment
Holbert, C. E., Casero, R. A., & Stewart, T. M. (2024) · Discover Oncology · doi:10.1007/s12672-024-01034-9 · Cited by 56
“Oh et al. have shown that glutamine availability is required for MDSC generation and recruitment [146].”
BackgroundAmino Acid Transport and Metabolism in Myeloid Function
Halaby, M. J., & McGaha, T. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.695238 · Cited by 50
“In addition, TAMs exhibited a more pro-inflammatory tumoricidal phenotype, with increased TNFa secretion, activation of Nf-kB and a reduction in STAT3 signaling and IL-10 production (54).”
BackgroundInfluentialWetzel, T. J., Erfan, S. C., Figueroa, L. D., Wheeler, L. M., & Ananieva, E. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1186539 · Cited by 47
Nanomedicine strategies for cuproptosis: Metabolic reprogramming and tumor immunotherapy
Zhang, R., Li, Y., Fu, H., Zhao, C., Li, X., Wang, Y., Sun, Y., & Li, Y. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.007 · Cited by 49
Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils
Russo, M., & Nastasi, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871513 · Cited by 48
Ma, G., Li, C., Zhang, Z., Liang, Y., Liang, Z., Chen, Y., Wang, L., Li, D., Zeng, M., Shan, W., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.697894 · Cited by 51
“The use of a small-molecule inhibitor of glutamine metabolism demonstrated that blockade of glutamine metabolism inhibited the generation and recruitment of myeloid-derived suppressor cells (MDSCs) via inhibition of the production of colony-stimulating factor 3 (CSF3), which enhanced the function of T cells in TME (64…”
BackgroundNutrient inputs and social metabolic control of T cell fate
Bacigalupa, Z. A., Landis, M. D., & Rathmell, J. C. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.009 · Cited by 48
Target neutrophil heterogeneity and plasticity in cancer
Ye, F., Guang, L., Li, H., & Cheng, L. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01731-0 · Cited by 47
“Targeting this pathway with glutaminase inhibitors has demonstrated potential in reducing neutrophil-mediated immunosuppression and enhancing anti-tumor immunity [194].”
Fahrmann, J. F., Tanaka, I., Irajizad, E., Mao, X., Dennison, J. B., Murage, E. N., Casabar, J. P., Mayo, J., Peng, Q., Çeliktaş, M., et al. (2022) · Cancers · doi:10.3390/cancers14102543 · Cited by 45
Parveen, S., Shen, J., Lun, S., Zhao, L., Alt, J., Koleske, B. N., Leone, R. D., Rais, R., Powell, J. D., Murphy, J. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43304-0 · Cited by 46
“JHU083 treatment increased the frequency of CD4 +T-cells and enhanced naive T-cell signatures in both models 6,7 .”
InfluentialSelf-citationMetabolic pathways fueling the suppressive activity of myeloid-derived suppressor cells
Goldmann, O., & Medina, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1461455 · Cited by 47
Siddiqui, S., & Glauben, R. (2022) · Cancers · doi:10.3390/cancers14010250 · Cited by 49
Leveraging microenvironmental synthetic lethalities to treat cancer
Metcalf, K. J., Alazzeh, A., Werb, Z., & Weaver, V. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143765 · Cited by 42
Song, C., Kim, N., Nam, R. H., Choi, S. I., Jang, J. Y., Kim, J. W., Na, H. Y., & Lee, H. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215780 · Cited by 44
Fan, Y., Xue, H., Li, Z., Huo, M., Gao, H., & Guan, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1345522 · Cited by 40
Progression of m6A in the tumor microenvironment: hypoxia, immune and metabolic reprogramming
Han, X., Zhu, Y., Ke, J., Zhai, Y., Huang, M., Zhang, X., He, H., Zhang, X., Zhao, X., Guo, K., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02092-2 · Cited by 46
“In addition, glutamine can also regulate macrophage activation and myeloid-derived suppressor cell (MDSCs) function, and then improve the body ’ s speci fi c immunity [110, 111].”
BackgroundTumor-associated macrophages in cancer: from mechanisms to application
Tang, W., Wang, X., Han, B., Jiang, S.-H., & Cao, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00396-y · Cited by 48
“TAMs undergo extensive metabolic reprogramming within the TME, the reprogramming critically influences their pro-inflammatory or anti-inflammatory polarization, revealing important therapeutic opportunities [156, 157].”
Johnson, R. L., Cummings, M., Thangavelu, A., Theophilou, G., Jong, D. D., & Orsi, N. M. (2021) · Cancers · doi:10.3390/cancers13246231 · Cited by 43
Guo, R., Wang, R., Zhang, W., Li, Y., Wang, Y., Wang, H., Li, X., & Song, J. (2025) · Cancer Control · doi:10.1177/10732748251316604 · Cited by 43
“113-115 In glioblastoma studies, GS upregulation was found to contribute to the polarisation of TAM towards a pro-tumourigenic phenotype.”
Yu, Q., Tu, H., Yin, X., Peng, C., Dou, C., Yang, W., Wu, W., Guan, X., Li, J. X., Yan, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880262 · Cited by 43
Zhong, H., Zhou, S., Yin, S., Qiu, Y., Liu, B., & Yu, H. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.06.014 · Cited by 45
Immunometabolic reprogramming, another cancer hallmark
Kumar, V., & Stewart, J. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125874 · Cited by 37
“Targeting glutamine metabolism also inhibits the tryptophan metabolism generating immunosuppressive kynurenine metabolites (138).”
BackgroundMetabolic reprogramming of the tumor microenvironment to enhance immunotherapy
Lim, S. A. (2024) · BMB Reports · doi:10.5483/bmbrep.2024-0031 · Cited by 40
“Moreover, Glutamate blockade enhances the ICI efficacy as well as overcoming the ICI resistance (e.g. anti-PD-1 and/or anti-CTLA-4) (56).”
BackgroundHan, J., Dong, L., Wu, M., & Ma, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160340 · Cited by 39
Targeting neutrophils: Mechanism and advances in cancer therapy
Yang, S., Jia, J., Wang, F., Wang, Y., Fang, Y., Yang, Y., Zhou, Q., Yuan, W., & Bian, Z. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1599 · Cited by 38
“107”
Kim, D.-H., Kang, Y. N., Jin, J., Park, M., Kim, D., Yoon, G., Yun, J. W., Lee, J., Park, S. Y., Lee, Y. R., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01214-1 · Cited by 38
Targeting amino acid-metabolizing enzymes for cancer immunotherapy
Grobben, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1440269 · Cited by 38
Amino acid metabolic reprogramming in tumor metastatic colonization
Wang, Z., Wu, X., Chen, H., & Wang, K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1123192 · Cited by 40
“This study suggests that targeting glutamine metabolism makes tumors susceptible to immunotherapy (57).”
BackgroundTargeting metabolic pathways to counter cancer immunotherapy resistance
Agarwala, Y., Brauns, T. A., Sluder, A. E., Poznansky, M. C., & Gemechu, Y. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.05.006 · Cited by 34
Role of Tumor Microenvironment in Prostate Cancer Immunometabolism
Wang, Y., Chen, Y., & Wang, J. (2025) · Biomolecules · doi:10.3390/biom15060826 · Cited by 42
Yang, S., Tan, H.-X., Lai, Z., Peng, H., Yang, H., Fu, Q., Wang, H., Li, D., & Li, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04639-x · Cited by 35
Leveraging macrophage metabolism for anticancer therapy: opportunities and pitfalls
Saha, P., Ettel, P., & Weichhart, T. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.02.005 · Cited by 36
Metabolic reprogramming of neutrophils in the tumor microenvironment: Emerging therapeutic targets
Huang, S., Shi, J., Shen, J., & Fan, X. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217466 · Cited by 36
Xing, Y., & Liu, C. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02683-7 · Cited by 37
Targeting MDSCs in cancer: emerging immunotherapeutic and metabolic strategies
Dash, S., Firmanty, P., Chomczyk, M., Mohanty, V., Ma, W., & Baran, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1749965 · Cited by 39
Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies
Luo, W., Napoleon, J. V., Zhang, F., Lee, Y. G., Wang, B., Putt, K. S., & Low, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816761 · Cited by 35
“and FGF that promote cancer cell and neovasculature proliferation (41, 42), and iv) discharge chemokines (e.”
BackgroundThe role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy
Ganjoo, S., Gupta, P., Corbali, H. I., Nanez, S., Riad, T. S., Duong, L. K., Barsoumian, H. B., Masrorpour, F., Jiang, H., Welsh, J. W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172931 · Cited by 35
“The study also reported that inhibiting glutamine metabolism could reduce immunosuppressive effects in the TME by inhibiting IDO expression and decreasing kynurenine levels, which could indirectly support T cell activation (113).”
BackgroundMetabolic Signaling in the Tumor Microenvironment
Clay, R., Li, K., & Jin, L. (2025) · Cancers · doi:10.3390/cancers17010155 · Cited by 36
Hu, S., Heng, H., Yang, F., Wang, M., Liu, G., Xiang, Y., & Miao, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1735873 · Cited by 33
Wang, D., Wang, F., Kong, X., Li, Q., Shi, H., Zhao, S., Li, W., Li, Y., & Meng, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113376 · Cited by 33
Targeting Metabolic Pathways of Myeloid Cells Improves Cancer Immunotherapy
Li, J., Bolyard, C. M., Xin, G., & Li, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.747863 · Cited by 32
“A recent report studied the role of a small molecule glutamine antagonist, 6diazo-5-oxo-L-norleucine (DON) on MDSCs (Oh et al., 2020).”
BackgroundZhang, Z., Bao, C., Jiang, L., Wang, S., Wang, K., Lu, C., & Fang, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1054233 · Cited by 38
“Furthermore, glutamine metabolism in cancer cells affects the recruitment of myeloid-derived suppressor ce l l s (MDSCs , an immunosuppress ive environmental factor) and decreases inflammatory TAMs, leading to checkpoint blockade-resistant tumors to be immunosuppressive (110).”
BackgroundLi, Z., Deng, Y., Sun, H., Tan, C., Li, H., Mo, F., Wang, Y., Li, J., Zhou, Z., & Sun, M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.05.013 · Cited by 31
Moinuddin, A., Poznanski, S. M., Portillo, A. L., Monteiro, J. K., & Ashkar, A. A. (2024) · Immunological Reviews · doi:10.1111/imr.13316 · Cited by 34
“192 Further research should assess whether blocking glutamine metabolism inhibition also enhanced NK cell anti-tumor functions.”
BackgroundZhao, J., Yang, Z., Tu, M., Meng, W., Gao, H., Li, M. D., & Li, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.608641 · Cited by 34
“Powell and colleagues reported that combining JHU83 with anti-PD1 antibody can dramatically improve anti-PD1 antitumor effects compared with anti-PD1 therapy alone (19, 60).”
BackgroundLiang, Y., He, J., Chen, X., Yin, L., Yuan, Q., Zeng, Q., Zu, X., & Shen, Y. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.86039 · Cited by 30
“This shows that increased glutamine levels in macrophages are associated with M2-type polarization and that targeting glutamine synthetase is a potential strategy for treating cancer[60].”
BackgroundHe, J. N., Gao, Y., Jing, L., Yang, H., & Liu, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1489701 · Cited by 33
Harnessing the microbiome for cancer therapy
Hajjar, R., Mars, R. A. T., & Kashyap, P. (2026) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01268-6 · Cited by 34
A glutamine ‘tug-of-war’: targets to manipulate glutamine metabolism for cancer immunotherapy
Pallett, L. J., Dimeloe, S., Sinclair, L. V., Byrne, A. J., & Schurich, A. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab010 · Cited by 29
“enhance the therapeutic efficacy of immune checkpoint blockade in immunotherapy-resistant tumours (59).”
BackgroundHarnessing Metabolic Reprogramming to Improve Cancer Immunotherapy
Liang, Y., Tan, Y., Chen, G., Fan, J., & Zhang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910268 · Cited by 31
“In other studies, the inhibition of tumor glutamine metabolism could decrease the recruitment and infiltration of MDSCs by increasing cell death and decreasing tumor CSF3 expression, and this led to an increase in inflammatory TAM differentiation and inhibited tumor growth [105].”
BackgroundMyeloid-derived suppressor cells (MDSCs) in brain cancer: challenges and therapeutic strategies
Parizi, M. S., Salemizadehparizi, F., Abdolhosseini, S., Vanaei, S., Manzouri, A., & Ebrahimzadeh, F. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00878-9 · Cited by 31
Krug, A., Martinez-Turtos, A., & Verhoeyen, E. (2021) · Cancers · doi:10.3390/cancers14010183 · Cited by 32
Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment
Wei, J., Hu, M., & Du, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845923 · Cited by 34
Katopodi, T., Petanidis, S., Anestakis, D., Charalampidis, C., Chatziprodromidou, I. P., Floros, G., Eskitzis, P., Zarogoulidis, P., Koulouris, C., Sevva, C. D., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1325360 · Cited by 34
Not just sugar: metabolic control of neutrophil development and effector functions
Ettel, P., & Weichhart, T. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae057 · Cited by 28
Jia, S., Bode, A. M., Chen, X., & Luo, X. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189166 · Cited by 31
Chen, S., Jiang, Y. L., Zheng, J., Li, P., Liu, M., Zhu, Y., Zhu, S., & Chang, S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.073 · Cited by 31
Tumor-instructed glutamine synthesis in cancer-associated fibroblasts promotes pro-tumor macrophages
Li, X., Møller, S. H., Park, J., Chuang, Y., Hsueh, P., Chang, T.-H., Kao, K., Gallart‐Ayala, H., Wang, Y., Peng, J.-J., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241426 · Cited by 34
Neural signaling modulates metabolism of gastric cancer
Rabben, H.-L., Andersen, G. T., Olsen, M. K., Øverby, A., Ianevski, A., Kainov, D. E., Wang, T. C., Lundgren, S., Grønbech, J. E., Chen, D., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102091 · Cited by 32
T cell metabolic reprogramming in acute kidney injury and protection by glutamine blockade
Lee, K., Thompson, E. A., Gharaie, S., Patel, C. H., Kurzhagen, J. T., Pierorazio, P. M., Arend, L. J., Thomas, A. G., Noel, S., Slusher, B. S., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.160345 · Cited by 32
“Given that we found that glutamine antagonism provided a protective effect on cisplatin-induced AKI, and the published antitumor effect of glutamine antagonism (20), combining glutamine blocking strategy with cisplatin-based chemotherapy regimens could”
Self-citationDifferential Effects of Glutamine Inhibition Strategies on Antitumor CD8 T Cells
Madden, M. Z., Ye, X., Chi, C., Fisher, E. L., Wolf, M. M., Needle, G. A., Bader, J. E., Patterson, A. R., Reinfeld, B. I., Landis, M. D., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200715 · Cited by 32
Shi, H., Yuan, X., Yang, X., Huang, R., Fan, W., & Liu, G. (2024) · BMC Genomics · doi:10.1186/s12864-024-10038-2 · Cited by 29
“Reduced metabolism of Gln favors pro-inflammatory M1 macrophages [11].”
BackgroundMacrophage heterogeneity and its interactions with stromal cells in tumour microenvironment
Cao, L., Meng, X., Zhang, Z., Liu, Z., & He, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01201-z · Cited by 32
“Accordingly, inhibiting glutamine metabolism showed an antitumour macrophage phenotype shift, including increased expression of TNF, TLR4, CD80 and CD86 but decreased expression of IL-10 [66].”
BackgroundIntersection of Immunology and Metabolism in Myocardial Disease
Thorp, E. B., & Karlstaedt, A. (2024) · Circulation Research · doi:10.1161/circresaha.124.323660 · Cited by 31
“50,64 Immune cell activation is driven by extracellular nutrients, which create metabolic pressures.”
BackgroundHe, J. N., Gao, Y., Sun, Z., & Liu, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529403 · Cited by 27
Peng, X., Zheng, T., Guo, Y., & Zhu, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.955705 · Cited by 28
Xu, Y., Xia, Z., Sun, X., Wei, B., Fu, Y., Shi, D., & Zhu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111319 · Cited by 29
“Consequently, it is also necessary to take into consideration glutamine metabolism from the perspective of tumor immunotherapy (13, 14).”
BackgroundOtegui, N., Houry, M., Arozarena, I., Serrano, D., Redín, E., Expósito, F., León, S., Valencia, K., Montuenga, L. M., & Calvo, A. (2023) · Cancers · doi:10.3390/cancers15123076 · Cited by 30
“Several reports have shown that, in the context of lung cancer, inhibition of glutamine metabolism can have the capacity to reactivate CD8+ T cells, reduce the MDSC population and even promote the expression of PD-L1 [137,138].”
BackgroundAllevato, M. M., Trinh, S., Koshizuka, K., Nachmanson, D., Nguyen, T., Yokoyama, Y., Wu, X., Andres, A. M., Wang, Z., Watrous, J. D., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217089 · Cited by 30
The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy?
Mojsilović, S. S., Mojsilović, S. B., Villar, V. H., & Santibanez, J. F. (2021) · Analytical Cellular Pathology · doi:10.1155/2021/5523055 · Cited by 28
Ying, L., Cheng, M., Lü, Y., Tao, Q., Chen, X., Shen, B., Xiong, F., Hu, Z., Wang, D., & Li, X. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.1610075 · Cited by 29
“Targeting GM rendered ICI-resistant tumors susceptible to immunotherapy by modulating myeloid-derived suppressor cells (MDSCs) in a breast cancer model [23].”
BackgroundLKB1: Can We Target an Hidden Target? Focus on NSCLC
Ndembe, G., Intini, I., Perin, E., Marabese, M., Caiola, E., Mendogni, P., Rosso, L., Broggini, M., & Colombo, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.889826 · Cited by 34
Metadata
- Authors
- Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., Englert, J. M., Arwood, M. L., Wen, J., Chan-Li, Y., Tenora, L., Majer, P., Rais, R., Slusher, B. S., Horton, M. R., & Powell, J. D.
- Affiliations
- Johns Hopkins University (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- UPMC Enterprises (United States) (US)
- Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry (CZ)
- Corresponding author
- Powell, Jonathan D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-06-15
- Volume
- 130
- Issue
- 7
- Pages
- 3865-3884
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3020598614
- Cited by
- 456
- References
- 66
- Citations by year
- 2026: 72 · 2025: 86 · 2024: 77 · 2023: 89 · 2022: 65 · 2021: 49 · 2020: 18
- FWCI
- 19.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH Office of the Director (R01CA229451, S10 OD016374, R01HL141490, R01AI077610, R01CA226765)
- Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University (N/A)
- Under Armour Women’s Health & Breast Cancer Innovation Grants (N/A)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- glutamine metabolism, myeloid-derived suppressor cells, tumor microenvironment, tumor-associated macrophages, immunogenic cell death, granulocyte colony-stimulating factor, IDO, kynurenine, immunometabolism, metastasis, antitumor immunity, small molecule inhibitors
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Female, Glutamine, Immunity, Cellular, Immunotherapy, Macrophages, Male, Mice, Inbred BALB C, Neoplasms, Experimental, Mice, Knockout, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.